-transparent.png){kind=logo}
A monoclonal antibody to human thyroglobulin was radiolabelled with 123I NaI and shown to be a stable and biologically active reagent in vivo. When injected intravenously into 12 patients with cancer of the thyroid on thyroxine-replacement therapy, 6 of the 12 patients had localization of the labelled antibody in tumour sites. These results were compared to 131I scans done on the same patients 1 month after stopping thyroxine. The biological half-life of the antibody in the blood was influenced by the levels of circulating thyroglobulin.
Related Publications
P S Shepherd, and
C R Lazarus, and
R D Mistry, and
M N Maisey
January 1987,
Histochemistry,
P S Shepherd, and
C R Lazarus, and
R D Mistry, and
M N Maisey
June 1983,
Clinical endocrinology,
P S Shepherd, and
C R Lazarus, and
R D Mistry, and
M N Maisey
December 1986,
Nuklearmedizin. Nuclear medicine,
P S Shepherd, and
C R Lazarus, and
R D Mistry, and
M N Maisey
June 1993,
Molecular and cellular endocrinology,
P S Shepherd, and
C R Lazarus, and
R D Mistry, and
M N Maisey
August 2019,
Scandinavian journal of immunology,
P S Shepherd, and
C R Lazarus, and
R D Mistry, and
M N Maisey
February 1989,
The Japanese journal of experimental medicine,
P S Shepherd, and
C R Lazarus, and
R D Mistry, and
M N Maisey
August 1989,
Immunology,
P S Shepherd, and
C R Lazarus, and
R D Mistry, and
M N Maisey
February 1993,
Cellular immunology,
P S Shepherd, and
C R Lazarus, and
R D Mistry, and
M N Maisey
January 1990,
European journal of cancer (Oxford, England : 1990),
P S Shepherd, and
C R Lazarus, and
R D Mistry, and
M N Maisey
August 1982,
Lancet (London, England),
